Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04282148 · ClinicalTrials.gov registry record · NA
Abbott Next Generation Drug Eluting Stent 48mm Study
A NA study of Coronary Artery Disease, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 107
- Enrollment target
- 20
- Study locations
NCT04282148: Completed NA study of Coronary Artery Disease, sponsored by Abbott Medical Devices.
NCT04282148 is a NA study of Coronary Artery Disease that has completed, run by Abbott Medical Devices. The registered enrollment target is 107 participants, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04282148, a NA study of Coronary Artery Disease, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 107 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this SPIRIT 48 study is to evaluate the safety and effectiveness of the ABT NG DES 48 in improving coronary artery luminal diameter in subjects with coronary artery disease (CAD) due to de novo native coronary artery long lesions.
Primary Outcome
Target Lesion Failure (TLF) is defined as the composite rate of cardiac death (CD), target vessel myocardial infarction \[TV-MI\] (per SCAI MI definition), and clinically indicated target lesion revascularization \[CI-TLR\])
Conditions Studied
Interventions
- DEVICE ABT NG DES 48 EECSS
Study Locations (20)
California
- Scripps Memorial Hospital - La Jolla - La Jolla
- UCLA Medical Center Santa Monica - Santa Monica
Florida
- The Cardiac & Vascular Institute Research Foundation, LLC - Gainesville
- Shands at the University of Florida - Gainesville
Kansas
- Via Christi Regional Medical Center - St. Francis Campus - Wichita
- Cardiovascular Research Institute of Kansas - Wichita
Ohio
- The Lindner Center - Cincinnati
- St. Vincent Mercy Medical Center - Toledo
Texas
- Baylor Scott & White Heart & Vascular Hospital - Dallas
- The Heart Hospital Baylor Plano - Plano
Arizona
- HonorHealth - Scottsdale
Massachusetts
- Massachusetts General Hospital - Boston
Minnesota
- Minneapolis Heart Institute - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2020-06-17 |
| Est. Completion | 2023-09-17 |
| Phase | NA |
What the finished NCT04282148 record still lists
NCT04282148 is an interventional study that assigns participants to a tested intervention. The registered 107 participants enrollment target is mid-sized for trials with a published cap, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which ABT NG DES 48 EECSS is the first listed.
NCT04282148 names 20 study sites across 15 states, led by California, Florida, Kansas.
Frequently Asked Questions
What is clinical trial NCT04282148 about?
NCT04282148 is a clinical study titled "Abbott Next Generation Drug Eluting Stent 48mm Study". The purpose of this SPIRIT 48 study is to evaluate the safety and effectiveness of the ABT NG DES 48 in improving coronary artery luminal diameter in subjects with coronary artery disease (CAD) due to de novo native coronary artery long lesions.
What is the current status of trial NCT04282148?
This trial is currently completed. It is a NA study. The enrollment target is 107 participants. The study started on 2020-06-17. Estimated completion is 2023-09-17.
What conditions does trial NCT04282148 study?
This clinical trial studies the following conditions: Coronary Artery Disease.
What interventions are being tested in trial NCT04282148?
The interventions under investigation include: ABT NG DES 48 EECSS (DEVICE).
Who is sponsoring clinical trial NCT04282148?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04282148 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Kansas, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04282148's enrollment target sits among peer trials
107 143rd of 219 higher than 76 of 219 other Coronary Artery Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
RECRUITING · NA
-
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
RECRUITING · NA
-
PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]
RECRUITING · NA
-
Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health
RECRUITING · NA
-
Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health
RECRUITING · NA
-
Intravascular Lithotripsy With or Without Rotational Atherectomy for Coronary Calcified Nodule Treatment
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06041594 · 107 participants · NA
Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)
- NCT06081426 · 107 participants · NA
Examining Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD)
- NCT06527599 · 107 participants · NA
Screening in Trauma for Opioid Misuse Prevention - an Adaptive Intervention
- NCT07096193 · 107 participants · Phase 1
Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI